Organometallic ruthenium(II)-arene complexes with triphenylphosphine amino acid bioconjugates: Synthesis, characterization and biological properties.

(p-Cymene)-ruthenium bioconjugates ML (1) and ML (2), bearing phosphane ligands substituted with chiral or non-chiral amino acid esters, L, were synthetized and characterized by instrumental methods (NMR, CD, MS) and DFT calculations (using the wB97xD functional). Cytotoxic activity of complexes 1 and 2 was investigated by using human cervical carcinoma cell line (HeLa) and MTT assay. Four (2, 2, 2 and 2) out of ten synthesized ruthenium complexes showed significant toxicity, with IC values of 5-30 μM.

The first case report of a large deletion of the BRCA1 gene in Croatia: A case report.

Rationale: Breast cancer is one of the most common cancers in women, and it is the leading cause of cancer related deaths in Croatia. BRCA1 and BRCA2 gene mutations are the most common cause of hereditary breast cancer.

Patient Concerns: In this report we describe a Croatian patient with no apparent family history of cancer, who developed breast cancer first at 29, and again at 33.

Discovery of 'click' 1,2,3-triazolium salts as potential anticancer drugs.

Background: In order to increase the effectiveness of cancer treatment, new compounds with potential anticancer activities are synthesized and screened. Here we present the screening of a new class of compounds, 1-(2-picolyl)-, 4-(2-picolyl)-, 1-(2-pyridyl)-, and 4-(2-pyridyl)-3-methyl-1,2,3-triazolium salts and 'parent' 1,2,3-triazole precursors.

Methods: Cytotoxic activity of new compounds was determined by spectrophotometric MTT assay on several tumour and one normal cell line.